Amedica Corporation Files Registration Statement for Proposed Public Offering

SALT LAKE CITY, Nov. 5, 2014 (GLOBE NEWSWIRE) -- Amedica Corporation (Nasdaq:AMDA), a biomaterial company that has developed silicon nitride ceramics as a material platform to manufacture and commercialize orthopaedic implants announced that it has a filed a registration statement on Form S-1 relating to a proposed public offering of its securities. The Company expects to offer units consisting of shares of common stock and warrants to purchase shares of common stock. The number of units to be offered and terms of the units have not yet been determined.

Dawson James Securities, Inc. is acting as sole book-running manager for the offering. When available, a copy of the preliminary prospectus may be obtained from Dawson James Securities, Inc., Attention: Prospectus Department, One North Federal Highway, 5th Floor, Boca Raton, FL 33432, e-mail: or toll free at 866.928.0928.

A registration statement relating to these securities has been filed with the United States Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Amedica Corporation

Amedica is a company focused on the development and application of medical-grade silicon nitride ceramics. Amedica markets spinal fusion products and is developing a new generation of orthopaedic bearings for hip and knee arthroplasty. Amedica operates an ISO 13485 certified manufacturing facility and its spine products are FDA cleared, CE marked, and currently marketed in the U.S. and select markets in Europe and South America.

CONTACT: Mike Houston Director of Investor Relations, Amedica 801-839-3534

Source:Amedica Corporation